Therefore, our preclinical data strongly suggest that the combination of osimertinib and a MET inhibitor should be always proposed to this subset of patients as for instance in the clinical case reported in Figure 4E. Our work is in accordance with previous clinical studies showing a poor response to crizotinib alone in patients with EGFR-mutated lung cancer with MET amplification [15]. This evidence concerns the gene MET and lung carcinoma.